Summary:
- This article discusses the announcement by Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, about four posters presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.
- The posters highlight the company's lead product candidate, azenosertib, which is being investigated for the treatment of various types of cancer, including acute myeloid leukemia (AML) and solid tumors.
- The posters provide updates on the preclinical and clinical development of azenosertib, demonstrating its potential efficacy and safety profile in treating these challenging cancer types.